Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Azitra Inc (AZTR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/30/2025: AZTR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.5
1 Year Target Price $4.5
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.69M USD | Price to earnings Ratio 0.02 | 1Y Target Price 4.5 |
Price to earnings Ratio 0.02 | 1Y Target Price 4.5 | ||
Volume (30-day avg) 1 | Beta -1.69 | 52 Weeks Range 0.47 - 4.33 | Updated Date 10/30/2025 |
52 Weeks Range 0.47 - 4.33 | Updated Date 10/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 26.97 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -180.76% | Return on Equity (TTM) -473.31% |
Valuation
Trailing PE 0.02 | Forward PE - | Enterprise Value 3515590 | Price to Sales(TTM) 438.62 |
Enterprise Value 3515590 | Price to Sales(TTM) 438.62 | ||
Enterprise Value to Revenue 220.15 | Enterprise Value to EBITDA -0.39 | Shares Outstanding 5404968 | Shares Floating 3506751 |
Shares Outstanding 5404968 | Shares Floating 3506751 | ||
Percent Insiders 0.52 | Percent Institutions 1.71 |
Upturn AI SWOT
Azitra Inc
Company Overview
History and Background
Azitra, Inc. is a clinical-stage medical dermatology company focused on developing therapies to protect skin health using its proprietary platform that combines a deep understanding of the skin microbiome with innovative genetic engineering. They were founded in 2014 and went public through a special-purpose acquisition company (SPAC) merger in 2023.
Core Business Areas
- Therapeutic Development: Azitra focuses on developing genetically engineered bacteria to treat skin conditions and diseases.
- Research and Development: The company invests in research to expand its understanding of the skin microbiome and develop new therapeutic candidates.
Leadership and Structure
Travis Whitfill is the CEO. The company has a board of directors and is structured around research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- ATR-12: ATR-12 is a genetically engineered strain of Staphylococcus epidermidis being developed for Netherton Syndrome. Currently in phase 1b trials. Competitors include companies developing gene therapies and biologics for similar genetic skin disorders, such as Novartis.
- ATR-04: ATR-04 is being developed to treat papulopustular rosacea. Competitors include companies focused on topical treatments for rosacea. Precise market share data is not currently available.
Market Dynamics
Industry Overview
The medical dermatology industry is growing, driven by increasing awareness of skin conditions and the development of new treatments. The market is competitive, with a mix of established pharmaceutical companies and smaller biotech firms.
Positioning
Azitra is positioned as an innovator in the skin microbiome therapeutic space, with a focus on genetically engineered bacteria. Their competitive advantage lies in their proprietary platform and focus on targeted therapies.
Total Addressable Market (TAM)
The total addressable market for Netherton Syndrome and rosacea therapeutics is estimated to be in the billions of dollars. Azitra is positioned to capture a portion of this market with its novel approach, however, this is highly speculative at this early stage.
Upturn SWOT Analysis
Strengths
- Proprietary platform technology
- Focus on unmet medical needs
- Strong scientific team
- Potential for first-in-class therapies
Weaknesses
- Early stage of development
- High risk associated with novel therapies
- Dependence on external funding
- Limited clinical data
Opportunities
- Expanding pipeline of therapeutic candidates
- Partnering with larger pharmaceutical companies
- Securing regulatory approvals
- Addressing additional skin conditions
Threats
- Competition from established companies
- Regulatory hurdles
- Clinical trial failures
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- NOVN
- SNY
- LLY
Competitive Landscape
Azitra competes with established pharmaceutical companies and smaller biotech firms in the dermatology space. Their advantage lies in their unique approach to targeting the skin microbiome.
Growth Trajectory and Initiatives
Historical Growth: Azitra's historical growth has been focused on preclinical and early-stage clinical development.
Future Projections: Future growth is dependent on successful clinical trials and regulatory approvals. Analyst estimates are unavailable.
Recent Initiatives: Recent initiatives include advancing ATR-12 into Phase 1b trials and expanding the pipeline with ATR-04.
Summary
Azitra is an early-stage biotech company with a novel approach to treating skin diseases using engineered bacteria. Their success depends on positive clinical trial results and securing regulatory approvals. While their technology is promising, they face significant risks associated with drug development and competition from established players. More information on their market cap will impact the fundamental rating.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Press Releases
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. The information provided is not guaranteed to be accurate or complete. Investing in early-stage biotech companies involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Azitra Inc
Exchange NYSE MKT | Headquaters Branford, CT, United States | ||
IPO Launch date 2023-06-16 | President, CEO & Director Mr. Francisco D. Salva | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | Website https://azitrainc.com |
Full time employees 12 | Website https://azitrainc.com | ||
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis that is in Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.